How many investments has Atlas Venture made?

Atlas Venture has 52 tracked investments, 2 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.

What stage does Atlas Venture invest at?

Atlas Venture invests at the Seed, Series A, Series B, Late Stage stages.

What is Atlas Venture's typical check size?

Atlas Venture typically writes checks of $500K – $1M.

What sectors does Atlas Venture focus on?

Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.

Where is Atlas Venture located?

Atlas Venture is headquartered in Cambridge, US.

Does Atlas Venture lead rounds?

Atlas Venture typically participates in rounds rather than leading them.

Who does Atlas Venture co-invest with?

Atlas Venture most often shares deals with F-Prime Capital, Foresite Capital, OrbiMed, among 64 tracked co-investors.

Atlas Venture

Venture capitalActively deployingoperating company · company profile

Cambridge · Seed–Late Stage · 22 people tracked

Also known as ATLAS VENTURE ADVISORS, INC. · Atlas Venture Ill · ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Atlas Venture focuses on medical and biotech innovation, backing early-stage life sciences companies. The firm operates an incubator through which it launches new startups, and its portfolio companies have developed approved medicines and achieved outcomes including IPOs and M&A exits. With roughly thirty years of experience, the firm positions itself at the leading edge of medical innovation.

Invests inBiotech Deep Tech Digital Health Healthtech Medical Devices Cambridge United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Late Stage

Check

$500K – $1M

Cambridge, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

1993

Last 12 months

4 investments

AUM

$3.2B

VC funds

Tracked investments

101

Team · 22 people

from the firm's website & curated & public directories

Bruce Booth· Partner· Wellesley, MAin 𝕏

Bruce Booth is a partner at Atlas Venture focused on the discovery and development of novel medicines and therapeutic platforms. He joined Atlas in 2005 after working as a consultant at McKinsey & Company and as an investor for Caxton Health Holdings. He holds a D.Phil. in molecular immunology from Oxford University, which he attended as a British Marshall Scholar, and a BS in biochemistry from The Pennsylvania State University.

b•••@atlasventure.comreveal

David Grayzel· Managing Director· Cambridge, Massachusetts, United Statesin

David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).

d•••@atlasventure.comreveal

Jason Rhodes· Partner· Cambridge, Massachusetts, United Statesin

Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.

j•••@atlasventure.comreveal

Jean-François Formela· Partner· Boston, Massachusetts, United Statesin

Jean-François Formela is a partner at Atlas Venture, where he focuses on novel drug discovery technologies and therapeutics. He joined the firm in 1993 to establish its U.S. life sciences practice. He holds an M.D. from Paris University School of Medicine and an M.B.A. from Columbia University.

j•••@atlasventure.comreveal

Kevin Bitterman· Partner· Cambridge, Massachusettsin 𝕏

Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.

k•••@atlasventure.comreveal

Michael Gladstone· Partner· Boston, Massachusettsin 𝕏

Michael Gladstone is a partner at Atlas Venture, which he joined in 2012, and works on forming new therapeutics companies. Before Atlas, he worked at L.E.K. Consulting on business development and corporate strategy for biopharma clients, and earlier led HIV vaccine research in the Viral Pathogenesis department at Beth Israel Deaconess Medical Center. He holds an AB in biochemical sciences from Harvard College.

m•••@atlasventure.comreveal

Aimee Raleigh· Principal· Boston, Massachusettsin 𝕏

Aimee Raleigh is a principal at Atlas Venture, where she works with founders building companies in therapeutics and biology. Before Atlas, she was a life sciences consultant at L.E.K. Consulting, advising pharmaceutical and biotech clients on strategy for early-stage therapies, asset diligence, and commercial planning. She holds a Ph.D. in bioengineering from the University of California, San Diego, and a B.S.E. in biomedical engineering from Duke University.

a•••@atlasventure.comreveal

Jernej Godec· Principal· Cambridge, Massachusettsin 𝕏

Jernej Godec is a Principal at Atlas Venture, where he works on building therapeutics companies and supporting company creation across multiple therapeutic areas. Before Atlas, he was on the investment team at Apple Tree Partners, focused on early-stage therapeutics investments and company formation. He holds a PhD in immunology from Harvard University, where he studied T cell biology, and a BA with honors in molecular and cell biology from UC Berkeley.

j•••@atlasventure.comreveal

Maurizio Fazio· Principal· Cambridge, Massachusettsin 𝕏

Maurizio Fazio is a principal at Atlas Venture, where he works on building companies that turn scientific and technological advances into new therapeutics. He earned his PhD in biological and biomedical sciences at Harvard University, studying genetic and epigenetic drivers of melanoma progression in Leonard Zon's lab, and previously was a research fellow at Memorial Sloan Kettering Cancer Center investigating epigenetic therapies for pediatric leukemia. During graduate school he held fellowships at Vida Ventures and Flagship Pioneering and taught courses at the Harvard Summer School; he holds an MD from Vita-Salute San Raffaele University in Milan.

Phillip Samayoa· Venture Partner· Cambridge, Massachusetts, United Statesin

Phillip Samayoa is a venture partner with over 15 years of experience as a biotech investor, executive, and company builder. He most recently was chief scientific officer and chief strategy officer at Generation Bio, where he built business development, portfolio strategy, and discovery research functions and raised over $750M across financings and partnerships. He was previously a principal on the Atlas investment team, co-founded Generation Bio and Dyne Therapeutics, and earlier held roles at Merck's MRL Ventures Fund and Flagship Pioneering; he holds a Ph.D. in systems biology from UC San Diego and dual B.S. degrees from MIT.

John Maraganore· Venture Partner· Boston, Massachusetts, United Statesin

Founding CEO of Alnylam Pharmaceuticals, which he led from 2002-2021, overseeing the development and commercialization of the first RNAi medicines. He is currently CEO of JMM Innovations and serves on numerous biopharma boards; he holds an M.S. and Ph.D. in biochemistry and molecular biology from the University of Chicago.

Jodie Morrison· Venture Partner· Massachusettsin

Jodie Morrison serves as CEO and Board Member at Q32 Bio Inc., a biotechnology company. She also holds positions as a venture advisor at Atlas Venture and serves on biotechnology company boards.

Rajesh Devraj· Venture Partner· Cambridge, Massachusettsin 𝕏

Steven Robinette· Venture Partner𝕏

Julia Pian· Senior Associate· United Statesin 𝕏

Julia Pian is a senior associate at Atlas Venture, where she invests in and helps build companies developing novel therapies. Before joining the firm, she completed her pediatrics residency at Boston Children's Hospital and Boston Medical Center, and she continues to practice as a pediatric hospitalist at Boston Medical Center. She holds an AB in chemical and physical biology from Harvard College, an MD from Harvard Medical School, and an MBA from Harvard Business School.

Justin Feng· Senior Associate· Cambridge, Massachusetts, United Statesin

Justin Feng is a senior associate at Atlas Venture, where he invests in and helps build companies developing novel therapeutics. He previously was a senior associate at MRL Venture Funds (the corporate venture arm of Merck & Co.) and a senior manager on the Transactions and Early Innovation Partnering teams at Johnson & Johnson, and earlier served as a principal scientist at GRO Biosciences. He holds a BS with High Honors from UC Berkeley and a Ph.D. in biology from Harvard Medical School, completed in the lab of George Church as a National Science Foundation Graduate Fellow.

Stella Paffenholz· Senior Associate· Boston, Massachusetts, United Statesin

Stella Paffenholz is a senior associate at Atlas Venture, where she builds and invests in early-stage companies developing therapies from novel biology. She was previously a principal on the investment team at Nextech Invest, investing from Series A through public markets, and earlier held roles at McKinsey & Company, Apollo Health Ventures, and Merck KGaA. She holds a PhD from Memorial Sloan Kettering Cancer Center, where she studied genetic determinants of cancer treatment response, along with an MS from the German Cancer Research Center/University of Heidelberg and a BS from the University of Bonn.

Chelsea Johnson· Senior Associate· Boston / New Englandin 𝕏

c•••@atlasventure.comreveal

Ommer Chohan· CFO· Greater Bostonin

Ommer Chohan is the CFO of Atlas Venture, which he joined in 2015, where he oversees the firm's financial, legal, and operations functions. Before Atlas, he served as CFO/COO at Summerhill Venture Partners, joining in 2006 as part of the team that spun the firm out from Bell Canada, and earlier held the role of VP-Finance at First Asset Management Inc. He holds a BA in Management from the University of Toronto, an MBA from Cornell University's Johnson School, and a Master of Legal Studies in Taxation from Washington University in St. Louis, and earned his CPA (Ontario) while at PwC.

o•••@atlasventure.comreveal

Nello Mainolfi· Advisor· Greater Bostonin

Nello Mainolfi is the Founder, President, and Chief Executive Officer of Kymera Therapeutics (NASDAQ: KYMR). He has held leadership roles in both large pharmaceutical companies and smaller biotech firms, with experience in company creation, team building, strategic partnering, and private and public offerings. At Kymera, his work is focused on developing a class of degrader medicines.

Josh Powers· Associate· Boston, Massachusettsin

Sarah Downey

Founder mafia

The Atlas Venture mafia →

13 people who came through Atlas Venture went on to found or lead other companies.

Nessan BerminghamAnalyst - Associate - Principle - PartnerFounded Korro Bio +2 Romesh SubramanianEntrepreneur In ResidenceFounded RaNA Therapeutics +2 Phillip SamayoaVenture PartnerFounded Generation Bio +2 Jason RhodesPartnerFounded Rectifypharma +1 Sumit AgarwalAssociateFounded Shape Security +1 Kevin BittermanPartnerFounded Editas Medicine John MaraganoreVenture PartnerFounded Alnylam Philip AustinAnalystFounded Enko Chem Graham O'KeeffeInvestment PartnerFounded DisplayLink Fred DestinGeneral PartnerFounded Stride Jodie MorrisonVenture PartnerFounded Q32 Bio

+ 2 more

What they invest in

from 85 of 101 portfolio companies

Biotech ×67Healthtech ×44Medical Devices ×15Deep Tech ×12AI & Machine Learning ×10Digital Health ×4Enterprise Software ×4SaaS ×4

HQs:United States×69Azerbaijan×1

Who they back

founder profiles across 18 portfolio companies

39%

solo founders

7 of 18 mapped founding teams

~3 yrs

old at investment

median across 10 dated deals

Founding team size:solo founder×72 founders×83 founders×14+ founders×2

Investments · 101 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 6 2024 · 6 2023 · 6 2022 · 2 2021 · 3 2020 · 2 2019 · 5 2018 · 3 2017 · 2 2016 · 2 2015 · 748 dated

Q32 Bioq32bio.com in 𝕏NASDAQ: QTTB✓ verified

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)Michael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)Lee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)David Appugliese(Senior Vice President, Head of People)

Co-investorsOrbiMed CU Healthcare Innovation Fund OUP (Osage University Partners)Sanofi Ventures Agent Capital

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)

Board seatJean-François Formela· per SEC Form D

Co-investorsage1 Avoro Capital Advisors EcoR1 Capital Foresite Capital

KALA BIOkalarx.comNASDAQ: KALAAug 2015SEC filingmedium confidence

BiotechArlington, US

Justin Hanes(Director)Kevin Pojasek(Executive Officer)Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)

Board seatKevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLongitude Capital SR One Capital Management Ysios Capital Lux Capital Third Rock Ventures

Korro Biokorrobio.com in 𝕏NASDAQ: KRROMay 2019

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)in

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D

Co-investorsMC Healthcare Ventures New Enterprise Associates (NEA)

Neuroneticsneurostar.com inNASDAQ: STIMApr 2015SEC filingmedium confidence

HealthtechMalvern, US

Mark R. Bausinger(Executive Officer)Christopher Thatcher(Executive Officer, Director)

BoardStephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)P. Sherrill Neff(Director)

Board seatKevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015

Co-investors1315 Capital Ascension Ventures

Spero Therapeuticssperotherapeutics.com inNASDAQ: SPROJul 2021SEC filingmedium confidence

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)Stephen Garbacz(Executive Officer)

BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)Vikas Goyal(Director)

Board seatJean-François Formela· per SEC Form D · $40M raise · filed Jul 2021

Co-investorsHEALTHCARE ROYALTY PARTNERS MRL Ventures Fund OUP (Osage University Partners)RA Capital Alphabet

Xilio Therapeuticsxiliotx.com inNASDAQ: XLOFeb 2021SEC filingmedium confidence

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Board seatDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +4 more

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess Biotechnology Bain Capital Life Sciences Foresite Capital Frazier Life Sciences OrbiMed

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)

BoardLawrence Klein, Ph.D.(Director)

Co-investorsMPM BioImpact Vida Ventures Forbion Hercules Capital, Inc.

Exelixisexelixis.com in 𝕏NASDAQ: EXEL

Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types.

BiotechHealthtechSan Francisco Bay Area, US

Johnson & Johnsonjnj.com in 𝕏NYSE: JNJ

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.

BiotechHealthtechMedical DevicesNew Brunswick, US

Joaquin Duatoin

Co-investorsAisling Capital NaviMed Capital Portland Seed Fund SPRINGROCK VENTURES The Column Group venBio Partners

Kymera Therapeuticskymeratx.com in 𝕏NASDAQ: KYMR

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Bessemer Venture Partners Hatteras Venture Partners MRL Ventures Fund Nextech Invest +3 more

Replimunereplimune.com in 𝕏NASDAQ: REPL

Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to kill tumors locally and trigger a systemic anti-tumor immune response.

BiotechHealthtech

Synlogicsynlogictx.com in 𝕏OTC: SYBX

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)

Co-investorsNew Enterprise Associates (NEA)NSG Ventures Pfizer Venture Investments Sofinnova Ventures Solasta Ventures OrbiMed

Unum Therapeuticscogentbio.com in 𝕏NASDAQ: COGT

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.

BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US

Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)

BoardBen Auspitz(Director)Liam Ratcliffe(Director)Bruce Booth(Director)in

Co-investorsF-Prime Capital

Antares Therapeuticsantaresrx.com in 𝕏May 2025✓ verified

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D

Co-investorsLightspeed Venture Partners Vida Ventures Omega Funds Tenmile Abingworth Biotechnology Value Fund

Comanche Biopharmacomanchebiopharma.com inJan 2024 · $75M✓ verified

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.

BiotechFemTechHealthtechConcord, US

Mike Young(Founder)T Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)Michael Young(Executive Officer)Thomas Scott Johnson(Executive Officer, Director)

Board seatDavid Grayzel· per SEC Form D

Co-investorsGV (Google Ventures)Broadview Ventures F-Prime Capital Lilly Asia Ventures New Enterprise Associates (NEA)

Ifmtheraifmthera.com in 𝕏Jun 2016✓ verified

IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.

BiotechHealthtechCambridge, US

Gary Glick(Mr. Glick is a director and the President of the Issuer.)Gary D. Glick(Founder)H. Martin Seidel(Chief Executive Officer)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D

Co-investorsAbingworth

Kinaset Therapeuticskinasettherapeutics.com in 𝕏Jul 2022✓ verified

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Board seatKevin Bitterman· per SEC Form D

Co-investors5AM Ventures RA Capital EQT Life Sciences Sixty Degree Capital Vivo Capital Gimv +1 more

Remix Therapeuticsremixtx.com in 𝕏Jan 2024✓ verified

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)

Board seatKevin Bitterman· per SEC Form D

Co-investorsForesite Capital The Column Group ARCH Venture Partners Decheng Capital

Calderatxcalderatx.com✓ verified

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)

Co-investorsJanus Henderson Investors LAV venBio Partners

Ethyrealbioethyrealbio.com in✓ verified

Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.

BiotechHealthtechCambridge, US

Niranjan Kameswaran(Chief Executive Officer)Jessica Stromme(Chief Development Officer)Kelly Foster(Chief Scientific Officer)Stephen Huang(Senior Vice President, Head of Clinical Development)Simon Read(Chairman of the Board and Independent Board Member)

Co-investorsAvoro Capital Advisors Medicxi

Judo Biojudo.bio in✓ verified

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.

BiotechHealthtechCambridge, US

Andrew Fraley(Co-founder)Alfica SehgalOMMER CHOHAN(Executive Officer)JAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)William Ho

Co-investorsDigitalis Ventures The Column Group Droia Ventures YK Bioventures

Lifordi Immunotherapeuticslifordi.comNov 2025 · $42M✓ verified

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtech

Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)

Co-investorsARCH Venture Partners Sanofi Ventures 5AM Ventures

nChroma Bionchromabio.com in 𝕏✓ verified

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD

Co-investorsNewpath Partners ARCH Venture Partners DCVC (Data Collective)F-Prime Capital 5AM Ventures DCVC Bio +1 more

Pheontxpheontx.com in✓ verified

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsBiotechnology Value Fund Forbion Lightspeed Venture Partners Research Corporation Technologies TCG Crossover

Rectifypharmarectifypharma.com in 𝕏✓ verified

Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.

BiotechDeep Tech

Rajesh Devraj(President and Chief Executive Officer)Robert Hughes(Chief Scientific Officer)Pol Boudes(Chief Medical Officer)

Co-investorsDC Investment Partners Longwood Fund

Sionnatxsionnatx.com in 𝕏✓ verified

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)

Co-investorsOrbiMed RA Capital

Vima Therapeutics, Inc.vimatx.com in✓ verified

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.

BiotechHealthtechMedical Devices

Bernard Ravina(Founder and Chief Executive Officer)Judy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)Ariel D. Jasie(Chief Business Officer and General Counsel)Tushar Misra(Chief Technical Officer)

Co-investorsFrazier Life Sciences Access Industries Access Biotechnology Canaan Partners

visit www.trianabio.comtrianabio.com in 𝕏✓ verified

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & CEO, Co-founder)

Co-investorsAscenta Capital Bessemer Venture Partners Lightspeed Venture Partners Pfizer Ventures RA Capital Pfizer Venture Investments

Aerovate Therapeutics, Inc.Aug 2020SEC filingmedium confidence

Developing drugs for rare cardiopulmonary disease.

Boston, US

Board seatDavid Grayzel· per SEC Form D · $75.8M raise · filed Aug 2020

Co-investorsSofinnova Ventures

Affinia Therapeuticsaffiniatx.com inOct 2025

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)Rick Modi(Chief Executive Officer, Board Member)

Board seatDavid Grayzel· per SEC Form D

Co-investorsEcoR1 Capital Eight Roads Ventures F-Prime Capital GV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover +1 more

Akero Therapeutics, Inc.Dec 2018SEC filingmedium confidence

HealthtechSouth San Francisco, US

Aaron Kantoff(Director)Mark Iwicki(Director)Graham Walmsley(Director)Jonathan Young(Executive Officer)Andrew Cheng(Executive Officer, Director)

BoardAaron Royston(Director)

Board seatKevin Bitterman· per SEC Form D · $45.5M raise · filed Dec 2018

Co-investorsvenBio Partners

Akriveia TherapeuticsJan 2018SEC filinghigh confidence

BiotechSkillman, US

Simon Tomlinson(Executive Officer, Director)

BoardThomas Beck(Director)Benjamin Auspitz(Director)

Board seatDavid Grayzel· per SEC Form D · $22.5M raise · filed Jan 2018

Amagma, Inc.Dec 2022SEC filingmedium confidence

HealthtechWaltham, US

Tillman Gerngross(Executive Officer, Director)

BoardAmy Schulman(Director)in

Board seatJean-François Formela· per SEC Form D · $10M raise · filed Dec 2022

Co-investorsPolaris Partners

Antegrin TherapeuticsDec 2014SEC filinghigh confidence

BiotechSt. Louis, US

George H. Capps, II(Executive Officer)Robert Karr(Executive Officer, Director)David W. Griggs(Director)Thomas P. Cirrito(Director)

BoardCharles Bolten(Director)

Board seatPeter BarrettRajesh Devraj· per SEC Form D · $26M raise · filed Aug 2017

Caldera Therapeutics, Inc.Jan 2026

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Xiaodi Su(Director)

Board seatMichael Gladstone· per SEC Form D

Co-investorsBain Capital Life Sciences Janus Henderson Investors LAV Omega Funds venBio Global Strategic venBio Partners +1 more

Chroma Medicine, Inc.Sep 2023SEC filingmedium confidence

Boston, US

Board seatKevin Bitterman· per SEC Form D · $135M raise · filed Sep 2023

Co-investorsNewpath Partners

Day One Biopharmaceuticalsdayonebio.com in 𝕏Feb 2021

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

BoardDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)Daniel Becker(Director)

Board seatMichael Gladstone· per SEC Form D

Co-investorsAccess Biotechnology Canaan Partners RA Capital The Column Group

Direct Vet MarketingJul 2015SEC filingmedium confidence

HealthtechPortland, US

Benjamin Shaw(Executive Officer, Director)David Shaw(Director)

BoardYumin Choi(Director)Philip Ferneau(Director)Edward McNamara(Director)

Board seatKevin Bitterman· per SEC Form D · $52.3M raise · filed Jul 2015

Euclises PharmaceuticalsNov 2015SEC filingmedium confidence

BiotechSt. Louis, US

Robert W. Karr(Executive Officer, Director)Bobby W. Sandage, Jr.(Executive Officer, Director)John Talley(Director)Robert J. Calcaterra(Director)

BoardCharles Bolten(Director)Rick Ryan(Director)

Board seatRajesh Devraj· per SEC Form D · $2.7M raise · filed Dec 2016

Co-investorsiSelect Fund Cultivation Capital Missouri Technology Corporation

Grobiogrobio.com in 𝕏Jul 2024SEC filingmedium confidence

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Board seatKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024

Co-investorsLeaps by Bayer REDMILE Digitalis Ventures Dreamers VC Rising Tide Innovation Endeavors +1 more

IFM CinqueNov 2019SEC filingmedium confidence

BiotechBoston, US

Gary Glick(Executive Officer, Director)Shelley Chu(Director)John Leonard(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

IFM ContinuaNov 2019SEC filingmedium confidence

BiotechBoston, US

John Leonard(Director)Gary Glick(Executive Officer, Director)Shelley Chu(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

IFM QuattroNov 2019SEC filingmedium confidence

BiotechBoston, US

Gary Glick(Executive Officer, Director)John Leonard(Director)Shelley Chu(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

IFM TreJul 2018SEC filingmedium confidence

BiotechBoston, US

Gary D Glick(Executive Officer, Director)Vincent Miles(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Aug 2018

Ikena Oncology, Inc.Jul 2025SEC filingmedium confidence

BiotechBoston, US

Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)

BoardOtello Stampacchia(Director)in

Board seatJean-François Formela· per SEC Form D · $75M raise · filed Jul 2025

Co-investorsBiotechnology Value Fund Foresite Capital Omega Funds OrbiMed RTW Investments L.P.

Morphic Holding, Inc.Jun 2016SEC filingmedium confidence

BiotechWaltham, US

Timothy Springer(Director)Praveen Tiprirneni(Executive Officer, Director)Robert Farrell(Executive Officer)

BoardBarbara Dalton(Director)Ramy Farid(Director)

Board seatKevin Bitterman· per SEC Form D · $51.5M raise · filed Jul 2016

Co-investorsOmega Funds Polaris Partners

Navitor Pharmaceuticalsnavitorpharma.com inDec 2015

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)

BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)

Board seatKevin BittermanJean-François Formela· per SEC Form D

Co-investorsage1 Brace Pharma Sanofi Ventures Polaris Partners SR One Capital Management

RaNA TherapeuticsJul 2015SEC filingmedium confidence

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)

Board seatJean-François Formela· per SEC Form D · $47.5M raise · filed May 2019

Co-investorsPfizer Venture Investments

Renasant Biorenasantbio.com in 𝕏Jul 2025 · $55M

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).

BiotechHealthtechBerkeley, US

Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)Emily Conley(Executive Officer, Director)

BoardEvan Caplan(Director)inCharlotte McKee(Director)

Board seatKevin Bitterman· per SEC Form D

Co-investors5AM Ventures OrbiMed Qiming Venture Partners USA

Scorpion Therapeuticsscorpiontx.comJul 2024

BiotechBoston, US

Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)

Board seatJean-François Formela· per SEC Form D

Co-investorsAvoro Capital Advisors EcoR1 Capital Frazier Life Sciences Nextech Invest Vida Ventures Lightspeed Venture Partners +2 more

Triana Biomedicines, Inc.Dec 2025SEC filingmedium confidence

Lexington, US

Board seatDavid Grayzel· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsOpenSky Ventures Third Rock Ventures

Aavantgardebioaavantgardebio.com

Co-investorsLongwood Fund

Accent Therapeuticsaccenttx.com in 𝕏Jan 2024

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsDroia Ventures EcoR1 Capital GV (Google Ventures)The Column Group JJDC Johnson & Johnson Innovation – JJDC +1 more

Akeroakerotx.com in 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsForesite Capital Frazier Life Sciences Scion Life Sciences The Innovation Space venBio Partners Versant Ventures

Alnylamalnylam.com in 𝕏

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical Devices

John Maraganore(Founder)inDr. Yvonne Greenstreetin

Co-investorsARCH Venture Partners Blackstone Life Sciences Cardinal Partners

Arkuda Therapeuticsarkudatx.com in

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsMission Biocapital Pfizer Venture Investments Pfizer Ventures

BE Biopharmabe.bio

Co-investorsAlta Partners ARCH Venture Partners DC Investment Partners Longwood Fund Nextech Invest Pathway to Cures+6 more

Carbon Blackcarbonblack.comFeb 2014

Waltham, US

Patrick Morley(Executive Officer, Director)Eric Pyenson(Executive Officer)Gordon Pothier(Executive Officer)

BoardRonald Nordin(Director)Jeff Fagnan(Director)Paul Maeder(Director)

Co-investors.406 Ventures Accomplice Evolution Equity Partners Founders Circle Capital Intel Capital Kleiner Perkins +4 more

CloudSwitchverizon.com in 𝕏

Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.

Cloud ComputingEnterprise SoftwareNew York, US

Co-investorsMatrix North Atlantic Capital Norwest Venture Partners

Clypdclypd.com

Advertising technology platform providing audience-based sales for television advertising.

Somerville, US

Joshua Summers(Executive Officer, Director, Promoter)Doug Hurd(Executive Officer, Director, Promoter)

BoardRyan Moore(Director)Lars Albright(Director)

Co-investorsBoston Seed Capital Transmedia Capital Tribeca Venture Partners Data Point Capital Freestyle Capital Western Technology Investment

CustomMadecustommade.com 𝕏

CustomMade designs and produces one-of-a-kind engagement rings and custom jewelry, working with customers through a collaborative process to sketch, refine, and select stones from a large inventory of diamonds and gemstones.

ConsumerDirect to ConsumerE-commerceDover, US

Seth Rosen(Executive Officer, Director)David Hauser(Director)Sasha Shusteff(Director)

Co-investorsFirst Round Capital Founder Collective GV (Google Ventures)Launch Capital NextView Ventures Schooner Capital

Diagonaltxdiagonaltx.com in

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Co-investorsEcoR1 Capital Frazier Life Sciences Sanofi Ventures

DisplayLinkdisplaylink.com in

DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.

Enterprise SoftwareHardwareSemiconductors

Co-investorsBalderton Capital Dag Ventures

docTrackrdoctrackr.com in

CybersecurityCambridge, US

Co-investorsBantam Group Techstars

Earnestearnest.ag in 𝕏

Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers.

AgTechBiotechRantoul, US

Eddy Mejia(Co-founder)inDr. Gabe Price(Co-founder)

Co-investorsAg Ventures Alliance AgLaunch Accelerator Boot64 Ventures Adams Street Partners Andreessen Horowitz Battery Ventures +4 more

Egaletegalet.comJan 2019

Egalet develops medicines for people living with moderate to severe pain, including approved and licensed pain products.

BiotechHealthtechMedical DevicesWayne, US

BARBARA A. CARLIN(SENIOR VICE PRESIDENT AND CHIEF ACCOUNTING OFFICER)ROBERT S. RADIE(CHIEF EXECUTIVE OFFICER)MARK STROBECK(EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER)MEGAN TIMMINS(SENIOR VICE PRESIDENT AND GENERAL COUNSEL)PATRICK M. SHEA(SENIOR VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER)Jeffrey M. Dayno(Chief Medical Officer)

Co-investorsSunstone Capital

F Starf-star.com

Co-investorsMC Healthcare Ventures

Fancredfancred.com in

Boston, US

Co-investorsTechstars Militello Capital

Gemini Therapeutics

BiotechCambridge, US

James McLaughlin(Executive Officer, Director)

BoardJean George(Director)Jason Rhodes(Director)Carl Gordon(Director)in

Co-investorsLightstone Ventures OrbiMed

Generation Biogenerationbio.com

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsForesite Capital F-Prime Capital Invus

GrabCADgrabcad.com in 𝕏Dec 2011acquired by Stratasys

Advanced ManufacturingDeep TechFintechHardwareSaaSCambridge, US

Indrek Narusk(Executive Officer)Hardi Meybaum(Executive Officer, Director)in

BoardDavid Skok(Director)

Co-investorsAsimov Ventures Heuristic Capital Partners Matrix Techstars Tera Ventures NextView Ventures

Grapevinegrapevinelogic.com inAcquired

Influencer marketing platform connecting brands with social content creators for performance-measured, whitelisted paid social campaigns.

Cambridge, US

Brendan Lattrell(Executive Officer, Director)

BoardDavid Balter(Director)

Co-investorsBantam Group Kae Capital Techstars Peak XV Partners

Grapevinegrapevine.org in 𝕏

Grapevine operates a platform for Giving Circles that enables groups to pool donations, manage members, and direct funds to nonprofits.

Impact & Social GoodSaaSSocial

Emily RasmussenJessan Hutchinson-Quillian

Co-investorsDiagram Capital Kae Capital Notation Capital Overton Venture Capital PJC Ulu Ventures +1 more

Grapevinego-grapevine.com in

Grapevine builds software that acts as a purchasing agent for healthcare buyers, comparing vendors, prices, and supply routes in real time to lower the cost of medical supplies.

B2B MarketplacesDigital HealthHealthtechLogistics & Supply ChainSaaSNew York, US

Luká Yancopoulos(CEO & Co-Founder)

Co-investorsThe MBA Fund Kae Capital Peak XV Partners

Horizon Therapeuticshorizontherapeutics.com in 𝕏acquired by Amgen

BiotechHealthtech

Co-investorsAvoro Capital Advisors New Enterprise Associates (NEA)

HotSpot Therapeuticshotspotthera.com in 𝕏

HotSpot Therapeutics is a drug discovery company developing small-molecule allosteric medicines by targeting "natural hotspots" — regulatory on/off switches on proteins.

AI & Machine LearningBiotechHealthtech

Co-investorsB Capital Group B4 Capital MRL Ventures Fund Sofinnova Partners Solasta Ventures SR One Capital Management

Ikenaoncologyikenaoncology.com in 𝕏

ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases.

BiotechHealthtechSan Diego, US

Co-investorsOrbiMed

K36 Therapeuticsk36tx.com in 𝕏Jun 2023 · $70M

A biotechnology company developing cancer therapies for patients with unmet medical needs.

BiotechHealthtech

Co-investorsF-Prime Capital Nextech Invest Eight Roads Ventures

Kailerakailera.com in 𝕏

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates for people living with obesity.

BiotechHealthtech

Co-investorsBain Capital Life Sciences Catalio Capital Management, LP

Kinveykinvey.com inacquired by Progress Software

Cambridge, US

Sravish Sridhar(Executive Officer, Director)Jon Karlen(Director)

BoardFrank Castellucci(Director)Braden Bohrmann(Director)William Burnham(Director)Brady Bohrmann(Director)

Co-investorsAvalon Ventures Management, Llc Bantam Group NTT DOCOMO Ventures Techstars Verizon Ventures

Mariana Oncologymarianaoncology.com in 𝕏Sep 2023 · $175M

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess Biotechnology Nextech Invest Forbion RA Capital

Matchpointtxmatchpointtx.com in 𝕏

Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.

AI & Machine LearningBiotechDeep Tech

Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)

Co-investorsSanofi Ventures Digitalis Ventures

Morphosysmorphosys.com in 𝕏acquired by Novartis

BiotechHealthtech

Jean-Paul Kress, M.D.in

Nimbusnimbus.greenSep 2023 · $210MDefunct

Advanced ManufacturingMobility & TransportationAnn Arbor, US

Lihang Nong(Founder)in

Co-investorsY Combinator GV (Google Ventures)

Nimbusnimbus.dev inSep 2023 · $210MDefunct

Nimbus provides automated cost optimization for Datadog customers, reducing their observability expenses without requiring manual intervention from engineering teams.

AI & Machine LearningData & InfrastructureEnterprise SoftwareSeattle, US

Kevin Lin(Founder)in

Co-investorsY Combinator GV (Google Ventures)

Nimbushirenimbus.com inSep 2023 · $210M

HireNimbus is a mobile platform that connects homeowners with vetted local home service professionals for booking, payment, and job tracking.

AI & Machine LearningFintechImpact & Social GoodMarketplacesPropTechSaaSAlexandria, US

Satadru Sengupta(Founder)in

Co-investorsSamvid Ventures Techstars GV (Google Ventures)

Obsidiantxobsidiantx.com in 𝕏

Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.

BiotechHealthtech

Peter Barrett(Co-founder & Board Member)Tom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)Parameswaran Hari(Chief Medical Officer)Julie Feder(Chief Financial Officer)Dana Alexander(Chief Technical Officer)

Co-investorsTCG Crossover Vertex Ventures HC

Overdog

Nashville, US

Steven Berneman(Executive Officer, Director)Hunter Hillenmeyer(Executive Officer, Director)

BoardStuart Larkins(Director)inEric Satz(Director)

Co-investorsChicago Ventures Mountain Group Capital

Plastiqplastiq.com in

Digital banking and financial services for small businesses

Co-investorsAccomplice Acorn Pacific Ventures Bling Capital Firebolt Ventures Management Company, Llc Flybridge Capital Partners Khosla Ventures +2 more

Recorded Futurerecordedfuture.comOct 2017Acquired

Recorded Future provides cyberthreat intelligence and AI-powered cyber defense capabilities to help organizations identify and neutralize critical threats.

AI & Machine LearningCybersecurityData & InfrastructureEnterprise SoftwareSomerville, US

Christopher Ahlberg(Executive Officer, Director)Staffan Truve(Director)

BoardLiautaud Bernard(Director)Rich Miner(Director)Jeff Fagnan(Director)Kevin Brown(Director)in

Co-investorsAccomplice Balderton Capital Baukunst Gula Tech Adventures Insight Partners MassMutual Ventures +1 more

Rodin Therapeuticsrodintherapeutics.com inAug 2017

HealthtechCambridge, US

Adam Rosenberg(Executive Officer, Director)

BoardBruce Booth(Director)Kees Been(Director)Samantha Singer(Director)

Co-investorsGV (Google Ventures)Hatteras Venture Partners Third Point Ventures JJDC Remeditex Ventures

SimpleReachsimplereach.com in

New York, US

Edward Kim(Executive Officer, Director)Kent Krekorian(Executive Officer)Hal Muchnick(Executive Officer, Director)

BoardBo Peabody(Director)Benjamin Sun(Director)Kirk Wolfe(Director)

Co-investorsMI Ventures Social Starts MK Capital Spring Mountain Capital

Third Harmonic Biothirdharmonicbio.com

Co-investorsBain Capital Life Sciences

Thumbnail for Immune Designin 𝕏Acquired

Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.

BiotechHealthtechMedical DevicesRahway, US

Co-investorsAisling Capital HM Venture Partners Sanderling Ventures SPRINGROCK VENTURES The Column Group

Traceneurotraceneuro.com in

Trivenitriveni.bio inOct 2024 · $115M

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

Vishal Patelin

Co-investorsBorealis Ventures Borealis Ventures Magnetic Ventures OrbiMed Ascenta Capital Fidelity Investments +3 more

Ubersenseubersense.com in

FintechBoston, US

Co-investorsBantam Group Techstars Boston Seed Capital

Vigil Neurosciencevigilneuro.com in 𝕏

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)

Co-investorsLightstone Ventures Vida Ventures Hatteras Venture Partners Longwood Fund

visit www.nimbustx.comnimbustx.com in

Nimbus Therapeutics designs and develops small molecule medicines using computational drug design and translational medicine.

BiotechDeep Tech

Co-investorsLightstone Ventures Pfizer Venture Investments

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 19

IPOs and acquisitions across the tracked portfolio

Q32 BioNASDAQ: QTTBIntellia TherapeuticsNASDAQ: NTLAKALA BIONASDAQ: KALAKorro BioNASDAQ: KRRONeuroneticsNASDAQ: STIMSpero TherapeuticsNASDAQ: SPROXilio TherapeuticsNASDAQ: XLODisc MedicineNASDAQ: IRONDyne TherapeuticsNASDAQ: DYNExelixisNASDAQ: EXELJohnson & JohnsonNYSE: JNJKymera TherapeuticsNASDAQ: KYMRReplimuneNASDAQ: REPLSynlogicOTC: SYBXUnum TherapeuticsNASDAQ: COGTGrabCADacq. by StratasysHorizon Therapeuticsacq. by AmgenKinveyacq. by Progress SoftwareMorphosysacq. by Novartis

Portfolio news

latest coverage across their companies

Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Simply Wall St News

Intellia Therapeutics · simplywall.st · Aug 18, 2026

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Disc Medicine · prnewswire.com · Aug 18, 2026

Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO

Spero Therapeutics · marketbeat.com · Aug 18, 2026

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law | Press Releases | daily-tribune.com

Exelixis · daily-tribune.com · Aug 16, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results - Ticker Report

Xilio Therapeutics · tickerreport.com · Aug 15, 2026

KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks.com

KALA BIO · tipranks.com · Aug 14, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Triveni · fiercebiotech.com · Aug 12, 2026

Q32 Bio boosts cash as losses narrow modestly | QTTB Quarterly Report (10-Q)

Q32 Bio · stocktitan.net · Aug 5, 2026

Public market activity · per SEC filings

what is this? ⓘ

1 insider ownership filing (Forms 3/4/5)

at Q32 Bio Inc. (QTTB)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Atlas Venture made?: Atlas Venture has 52 tracked investments, 2 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
What stage does Atlas Venture invest at?: Atlas Venture invests at the Seed, Series A, Series B, Late Stage stages.
What is Atlas Venture's typical check size?: Atlas Venture typically writes checks of $500K – $1M.
What sectors does Atlas Venture focus on?: Atlas Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Atlas Venture located?: Atlas Venture is headquartered in Cambridge, US.
Does Atlas Venture lead rounds?: Atlas Venture typically participates in rounds rather than leading them.
Who does Atlas Venture co-invest with?: Atlas Venture most often shares deals with F-Prime Capital, Foresite Capital, OrbiMed, among 64 tracked co-investors.

Co-investors · 127

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 9

Disc Medicine Q32 Bio Synlogic Gemini Therapeutics Ikena Oncology, Inc.Ikenaoncology Renasant Bio Sionnatx Triveni

$1M – $75M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 7

Unum Therapeutics Xilio Therapeutics Affinia Therapeutics Comanche Biopharma Generation Bio K36 Therapeutics nChroma Bio

$3M – $10M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 7

Spero Therapeutics Xilio Therapeutics Day One Biopharmaceuticals Kinaset Therapeutics Mariana Oncology Sionnatxvisit www.trianabio.com

The Column Group

The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.

Both backed · 7

Johnson & Johnson Accent Therapeutics Day One Biopharmaceuticals Judo Bio Remix TherapeuticsBE BiopharmaThumbnail for Immune Design

$30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 6

Accent Therapeutics Affinia Therapeutics Comanche Biopharma CustomMade Nimbus Rodin Therapeutics

$250K – $50M

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 6

Kymera Therapeutics Q32 Bio Diagonaltx Lifordi Immunotherapeutics Navitor PharmaceuticalsMatchpointtx

$5M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 6

Kymera Therapeutics Synlogic Arkuda Therapeutics RaNA Therapeuticsvisit www.nimbustx.comvisit www.trianabio.com

$5M – $20M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Both backed · 6

Disc Medicine Intellia Therapeutics Akero Generation Bio Ikena Oncology, Inc.Remix Therapeutics

Omega Funds

Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.

Both backed · 6

Antares Therapeutics Caldera Therapeutics, Inc.Ikena Oncology, Inc.Morphic Holding, Inc.nChroma Bio Scorpion Therapeutics

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 5

Korro Bio Synlogic Affinia Therapeutics Comanche BiopharmaHorizon Therapeutics

$200K – $40M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 5

Alnylam Lifordi Immunotherapeutics nChroma Bio Remix TherapeuticsBE Biopharma

$50K – $250M

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 5

Johnson & Johnson Akero Akero Therapeutics, Inc.Caldera Therapeutics, Inc.Calderatx

▶115 more co-investors

Nextech Invest Lightspeed Venture Partners 5AM Ventures Vida Ventures Longwood Fund Polaris Partners Accomplice SR One Capital Management Forbion Digitalis Ventures Hatteras Venture Partners Bessemer Venture Partners First Round Capital Canaan Partners Third Rock Ventures Vivo Capital Leaps by Bayer Andreessen Horowitz Sequoia Capital Founder Collective DCVC (Data Collective)Innovation Endeavors EQT Life Sciences Sofinnova Partners Founders Circle Capital Johnson & Johnson Innovation – JJDC MPM BioImpact SV Health Investors Access Industries Ysios Capital Borealis Ventures Broadview Ventures General Catalyst Craft Ventures Accel Greylock Partners Index Ventures Redpoint Ventures Uncork Capital Felicis Ventures SV Angel Menlo Ventures BoxGroup CRV (Charles River Ventures)DST Global ACME Capital FirstMark Capital Slow Ventures HCVC AME Cloud Ventures Accel-KKR Kapor Capital Cota Capital Stride VC Practical Venture Capital Crosslink Capital Point Nine Pareto Holdings Entrepreneur First Entrée Capital General Atlantic HV Capital AlleyCorp Passion Capital Wildcat Venture Partners 83North Peak Breakthrough Energy Ventures FELIX CAPITAL Capital Factory Walden International LocalGlobe MMC Ventures Hoxton Ventures Blue Owl Capital Playground Global Motier Ventures NGP Capital Highbury Holdings BIOSPRING PARTNERS 20VC IrishAngels Angel Invest GE Ventures Jigsaw VC Mangrove Capital Partners Episode1 Kima Ventures Motivate Venture Capital Day One Ventures Pillar VC Allen Institute for Artificial Intelligence Incubator (AI2)AlbionVC Autotech Ventures Haatch Pivotal Life Sciences Novartis Venture Fund Kurma Partners Signal Peak Ventures Axeleo Capital Beyond Capital Andera Partners Advent Life Sciences Roche Venture Fund New Leaf Venture Partners Cornerstone VC Journey Ventures JMI Equity Fortino Capital ACORN BIOVENTURES Idinvest Partners Sherpa Ventures Altitude Ventures Management, Llc Nest.Bio Ventures Aditum Bio

Firms observed investing alongside Atlas Venture, from public investor directories. Shared companies are the overlap with Atlas Venture's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.